South Korea-based Samsung Biologics (207940.KS) has signed a strategic partnership with Kanaph Therapeutics, it was reported on Wednesday.
The contract has been signed to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
According to Kanaph Therapeutics, the product is aimed at autoimmune diseases by inhibiting the alternative pathway of the complement system. According to the contract, Samsung Biologics is to offer a complete scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission.
GLOBAL announces USD1m grants from NIH and Fast to study COVID-19 in people with Down Syndrome
Clover Biopharmaceuticals Forms Global Scientific Advisory Board for its COVID-19 Vaccine Programme
Gilead and Eisai announce Japanese approval of Jyseleca rheumatoid arthritis treatment
Cyxone revises development plan for Rabeximod to include rheumatoid arthritis and COVID-19 trials
Samsung Biologics signs strategic partnership with Kanaph Therapeutics
European authority issues positive opinion for baricitinib to Eli Lilly and and Incyte